Venkys (India) Ltd

- As per the management discussion on Page 19, there are **no current plans to increase liabilities** either through term loans or working capital loans. - The company currently has sufficient working capital availability of around INR160 crores to meet requirements. - On the capital expenditure front, the company intends to focus on strengthening existing units before considering any further capex (Page 14). - No mention of any upcoming equity fundraising or share buyback programs was confirmed, though shareholder suggestions on buyback have been noted and will be considered (Page 13). - Overall, Venky's India Limited is maintaining a conservative approach toward debt and capital infusion, with no immediate fundraising plans through debt or equity.

- Venky's plans to focus on strengthening existing units over the next year before considering further capex. - No immediate plans for increasing working capital or term loans; sufficient working capital (~INR160 crores) is in place. - No specific announcements about new capex in Oil Processing; current capacity utilization is improving with expectations to reach ~80%. - The company is cautious about adding new liabilities or investments amidst volatile raw material pricing. - Expansion in distribution channels for Animal Health is underway, but no direct capex details shared. - Management is exploring export opportunities but did not specify capital allocation. - Future capex decisions, including geographic expansion in Oil Processing, will be considered after stabilizing current facilities.

- Poultry segment growth expected at 7%-8% industry level; Venky's also plans internal growth in layers and broilers. - Layer chicks sales planned to increase from 4.57 crores in '25-'26 to over 5 crores in '26-'27. - Broiler chick and contract broiler farming (CBF) volumes targeted to grow by 4%-5%. - Animal Health business expected to achieve 15%-20% growth with continued double-digit expansion. - Soya business EBITDA and top line anticipated to maintain current run rates and contribute to growth. - Oil processing business recovery seen since FY24 with steady margins going forward. - Incremental growth largely expected from outside the group through expanded distribution channels. - SPF egg capacity utilization likely to improve beyond current 48%. Overall, Venky's aims for consistent volume and revenue growth across poultry, animal health, and soya segments with less volatility in poultry prices.

- Animal Health division expected to grow at double-digit rates, with 15%-20% growth guidance for FY27. Margins likely to sustain at 22%-23%+ despite some raw material cost pressures (Pages 16, 19). - Soya/Oil Seed division showing improved margins and volumes, targeting increased external sales (up to 65% outside group), hence better profitability; sustainable EBIT margin around 5%, with optimism for growth linked to better crops and export markets (Pages 16, 17). - Poultry division growth aligned with industry growth of 7%-8%, with some seasonality expected; volatility expected to reduce due to industry maturation and consistent placement practices (Pages 4, 18). - SPF egg division capacity utilization improving (48%) with scope for higher realization and margins, though precise margin outlook to be provided later (Page 16). - Overall, combined EBITDA run rate from Animal Health and Soya projected around INR160-180 crores, with top-line and margin expansion expected across segments (Page 16).

The provided transcript and pages do not explicitly mention details regarding Venky's India Limited's current or expected order book or pending orders. Key discussions focus on: - Poultry segment growth plans (layer chicks increasing from 4.57 crores to 5 crores in FY '26-'27). - Broiler segment growth expected at 4%-5% in contract broiler farming. - Expansion largely driven by existing players (over 75% expansion). - Volatility in poultry prices expected to reduce as market matures. - No direct mention or data on order book or pending orders in the excerpts provided. Therefore, no specific information is available on current or expected order book or pending orders in the disclosed call transcript.